The spectrum of cancer research addressed by these scholars encompasses an intricate network of biological pathways that govern tumor initiation, progression, and immune evasion—areas that remain critical frontiers with substantial implications for improving clinical outcomes. The Pew-Stewart program’s commitment to fostering innovative approaches is evident in the novel investigative trajectories pursued by this cohort, each aimed at solving complex mechanistic puzzles that underpin malignancy.

Dr. Sarah Aitken from Yale University embarks on a nuanced exploration of the genesis and evolution of cancerous mutations at the molecular and genomic levels. By integrating high-resolution molecular biology techniques with sophisticated image analysis pipelines, Dr. Aitken aims to characterize mutational processes that initiate oncogenesis and drive tumor heterogeneity. Her research promises to delineate how mutations accumulate and propagate, potentially unveiling targets for early intervention.

At the Memorial Sloan Kettering Cancer Center, Dr. Alexander Gitlin’s work interrogates the crosstalk between inflammatory signaling and programmed cell death pathways. Inflammation is a double-edged sword in cancer, capable of both promoting and hindering tumor growth. Dr. Gitlin seeks to map the signaling circuits orchestrating immune responses in both physiological and pathological contexts, leveraging cellular and molecular endocrinology to understand how inflammation modulates tumor microenvironment dynamics.

Dr. Anna-Maria Globig from the Allen Institute takes on the intricate bidirectional communication between nervous and immune systems, an emerging paradigm in cancer immunology. Her research focuses on deciphering neuroimmune interactions that influence antitumor immunity, with the goal of identifying novel therapeutic strategies to potentiate the immune system’s capacity to target and eradicate cancer cells.

Within the University of California, San Francisco, Dr. Roarke Kamber’s investigations probe the role of macrophages—innate immune cells known for their plasticity—in tumor biology. His research aims to unravel how macrophages engage with neoplastic cells within the tumor microenvironment, potentially repurposing these interactions to develop macrophage-based immunotherapies that can modulate tumor progression and response to treatment.

At the University of California, Berkeley, Dr. Ahmad Nabhan focuses on the nuanced signaling networks between stem cells and their immediate milieu. Given that stem cells often serve as reservoirs for cancer initiation and resistance, Dr. Nabhan’s work to decode and recode this communication is vital. By elucidating these interactions, his research aspires to develop precision therapeutics that can disrupt aberrant stem cell niches and inhibit malignancy.

This cohort exemplifies how interdisciplinary approaches, combining genomics, immunology, stem cell biology, and systems neuroscience, are fundamental to confronting the heterogeneous and adaptive nature of cancer. The integration of cutting-edge technologies, such as single-cell sequencing, advanced imaging, and computational modeling, underpins these investigations, promising not only to illuminate core principles of tumor biology but also to translate findings into innovative clinical interventions.

The collaboration between The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust underscores the importance of sustained investment in scientific excellence and early-career investigators, whose creativity and bold hypotheses drive the next wave of discovery. This program supports scholars not merely with funding but also by fostering a community of interdisciplinary communication, accelerating knowledge-sharing and collaborative innovation.

Such comprehensive efforts are crucial as cancer remains a leading cause of morbidity and mortality worldwide. These researchers’ endeavors are grounded in the understanding that cancer is not a singular disease but a constellation of disorders, each characterized by distinct genetic, immunologic, and microenvironmental contexts. Tailoring research to these nuances is indispensable for achieving breakthroughs in precision oncology.

The impact of the Pew-Stewart Scholars extends beyond laboratories and clinical trials; their foundational research feeds into a larger ecosystem of cancer research infrastructure. By elucidating fundamental biology while simultaneously seeking therapeutic leverage points, these scientists contribute to a continuum that spans basic science, translational hurdles, and patient-centered care advancements.

Over the years, the Pew-Stewart program has been instrumental in propelling revolutionary insights and fostering leaders within the oncology research community. The 2026 class stands poised to continue this tradition of excellence, armed with innovative tools and unique perspectives that reflect the rapidly evolving landscape of cancer research technologies and methodologies.

Each scholar’s vision represents a crucial strand in the multifaceted effort to combat cancer: from pinpointing the molecular triggers of mutation, decoding inflammatory pathways, harnessing immune-neural communication, manipulating immune cell behavior, to redefining stem cell niches. Collectively, their investigations hold promise for unlocking new paradigms in cancer treatment that could transform patient prognosis and quality of life.

As cancer research strides into an era characterized by unprecedented technological sophistication and collaborative potential, programs like Pew-Stewart exemplify how strategic support of emerging scientists accelerates the pace of discovery. Their breakthroughs will not only deepen our mechanistic understanding of cancer but also pave the way for personalized, effective, and less toxic treatment modalities.

By investing in visionary early-career investigators, the Pew Charitable Trusts and the Alexander and Margaret Stewart Trust reinforce a legacy of scientific innovation that fuels hope for millions affected by cancer worldwide. As these five scholars embark on their research trajectories, the oncology community eagerly anticipates the groundbreaking discoveries that will define the future of cancer research and therapy.

Subject of Research: Cancer biology, cancer immunology, tumor microenvironment, molecular mechanisms of cancer initiation and progression, neuroimmune interactions, stem cell niche signaling, inflammatory pathways, and therapeutic development.

Article Title: Pew-Stewart Scholars Drive Next-Generation Cancer Research Through Multi-Disciplinary Innovation

News Publication Date: 2024

Web References:
– Pew Charitable Trusts: https://www.pewtrusts.org/
– Alexander and Margaret Stewart Trust: https://www.stewart-trust.org/

Keywords: Cancer research, oncology, cancer immunology, molecular biology, genomics, inflammation, tumor microenvironment, stem cells, neuroimmune communication, macrophages, cancer therapeutics

The multidisciplinary research team employed advanced microscopy techniques to explore the physical and functional nature of contacts between SCLC cells and neurons. Using co-culture systems involving SCLC cells and cortical neurons, investigators applied immunostaining targeting glutamatergic vesicles, specifically using antibodies against vesicular glutamate transporter 1 (VGluT1), and postsynaptic scaffold protein HOMER1. This approach revealed closely juxtaposed puncta indicative of synaptic-like formations directly at the interface of neurons and cancer cells, a phenomenon rarely documented in non-neuronal malignancies.

To ascertain whether these observations extended beyond one experimental model, the researchers utilized human induced pluripotent stem (iPS) cell-derived cortical neurons. These cultures demonstrated consistent synaptic marker colocalization, marked by presynaptic expression of Bassoon in neurons and postsynaptic localization of HOMER1 within SCLC cells. This cross-validation across species and cellular models reinforces the hypothesis of neuron-to-cancer cell synaptic communication.

Further validating the anatomical and physiological relevance of these synapses, the team incorporated mouse nodose ganglia into co-cultures. This peripheral nervous system cluster is known to innervate pulmonary neuroendocrine cells (PNECs), posited as the origin of VGluT1-positive fibers identified in vivo within tumors. Imaging revealed continued juxtaposition of presynaptic VGluT1 and postsynaptic HOMER1 within SCLC cells, confirming that circuits resembling canonical synapses can form under diverse biological contexts.

Transitioning from in vitro systems to in vivo settings, the researchers examined brain allografts containing SCLC cells expressing fluorescent markers. Confocal and electron microscopy analyses identified HOMER1-positive postsynaptic structures in close proximity to axonal boutons labeled by enhanced green fluorescent protein (eGFP), signs of functional synapses. Lung tissue sections from genetically engineered, Cre-exposed RP mice revealed similar contacts at tumor margins, demonstrating that synapse-like interfaces between neurons and cancer cells occur naturally in complex tissue environments.

To achieve nanoscale resolution necessary for definitive structural characterization, the study employed tenfold expansion microscopy (x10ht), attaining spatial resolution near 25 nanometers. Three-dimensional reconstructions of cortical neuron–SCLC co-cultures revealed the spatial organization of presynaptic VGluT1-positive puncta positioned adjacent to postsynaptic HOMER1 immunoreactivity in cancer cells. This spatial fidelity is consistent with the nanometer-scale architecture of classical excitatory synapses in the central nervous system.

To push resolution boundaries further, the investigators applied one-step nanoscale expansion (ONE) microscopy, a super-resolution technique affording even finer visualization of synaptic components. Both three-dimensional and two-dimensional imaging modalities highlighted clear segregation of pre- and postsynaptic elements. Quantitative measurements revealed that the physical distance between VGluT1 and HOMER1 puncta at neuron–cancer cell contacts mirrored that observed at established neuron–neuron synapses within the same cultures, strengthening the assertion of synaptic conformity.

Correlative light and electron microscopy (CLEM), integrating high-resolution fluorescence imaging with ultrastructural analysis, constituted a pivotal validation strategy. Electron tomograms of fluorescently labeled SCLC cells in brain allografts revealed presynaptic boutons densely packed with synaptic vesicles in direct contact with cancer cell membranes. The presence of clearly defined synaptic clefts and vesicle pools within 20 nanometers from the presynaptic membrane echoed canonical synapse ultrastructure, affirming the authenticity of these specialized cell junctions.

A systematic examination of 280 cell perimeters at the periphery of the cancer allografts indicated that approximately 8.2% of SCLC cells formed synapses with axonal boutons, a substantial proportion given the heterogeneity of tumor microenvironments. This prevalence underscores the biological significance of these synaptic interactions and suggests potential roles in tumor progression, neuro-immune modulation, or therapeutic resistance mechanisms.

The discovery of synaptic connections between neural axons and SCLC cells challenges the traditional view of tumor biology as an exclusively cell-autonomous process, highlighting instead a dynamic neuro-cancer interface that may influence cancer cell behavior. Such functional synapses could mediate bidirectional communication, enabling neurons to modulate cancer cell signaling pathways and, reciprocally, cancer cells to influence neuronal circuitry.

Beyond structural characterization, these findings prompt intriguing questions regarding the nature of synaptic transmission between neurons and SCLC cells. Functional assays addressing whether neurotransmitter release at these synapses affects cancer proliferation, survival, or metastatic potential could expand understanding of how neuronal inputs integrate into tumor biology.

Moreover, this research paves the way for exploring synaptic-targeted therapies in oncology. Drugs disrupting synaptic machinery or modulating glutamatergic signaling might impair tumor growth or sensitize cancer cells to existing treatments. Given the critical role of synaptic proteins like VGluT1 and HOMER1 in these interfaces, they emerge as promising biomolecular targets for drug development.

The technological innovations applied, combining expansion microscopy with super-resolution and CLEM, exemplify state-of-the-art approaches to dissecting tumor microenvironments at near-molecular resolution. Such methodologies can be heralded as essential tools for future investigations into other cancer types and their interactions with the nervous system.

This seminal study offers a paradigm shift, revealing that SCLC cells can integrate into neural networks through bona fide synapses, thereby participating in complex cellular dialogues previously unappreciated in cancer research. As neuroscience and oncology converge, the characterization of tumor–neuron synapses heralds a new frontier with profound implications for cancer biology and therapeutic strategy.

Subject of Research: Synaptic interactions between neurons and small cell lung cancer cells.

Article Title: Functional synapses between neurons and small cell lung cancer.

Article References: Sakthivelu, V., Schmitt, A., Odenthal, F. et al. Functional synapses between neurons and small cell lung cancer. Nature (2025). https://doi.org/10.1038/s41586-025-09434-9

Image Credits: AI Generated